Show simple item record

FieldValueLanguage
dc.contributor.authorPathirana, Thanya
dc.contributor.authorHayen, Andrew
dc.contributor.authorDoust, Jenny
dc.contributor.authorGlasziou, Paul
dc.contributor.authorBell, Katy J.L.
dc.date.accessioned2021-04-14T07:00:13Z
dc.date.available2021-04-14T07:00:13Z
dc.date.issued2019en
dc.identifier.urihttps://hdl.handle.net/2123/24925
dc.description.abstractThe objective of this study was to quantify the risk of overdiagnosis associated with prostate cancer screening in Australia using a novel lifetime risk approach. Authors used modelling and validation of the lifetime risk method using publicly available population data. Participants included Australian male population (1982–2012). Focus on Prostate-specific antigen testing for prostate cancer screening.en
dc.language.isoenen
dc.publisherBMJ Publishing Groupen
dc.relation.ispartofBMJ Openen
dc.rightsCreative Commons Attribution-NonCommercial 4.0en
dc.subjectoverdiagnosisen
dc.subjectprostatic neoplasmsen
dc.subjectcanceren
dc.subjectscreeningen
dc.subjectProstate-specific antigenen
dc.titleLifetime risk of prostate cancer overdiagnosis in Australia: quantifying the risk of overdiagnosis associated with prostate cancer screening in Australia using a novel lifetime risk approach.en
dc.typeArticleen
dc.subject.asrc1112 Oncology and Carcinogenesisen
dc.subject.asrc1117 Public Health and Health Servicesen
dc.identifier.doi10.1136/bmjopen-2018-022457
dc.relation.nhmrc1080042
dc.relation.nhmrc1104136
dc.relation.nhmrc1113532
usyd.facultySeS faculties schools::Faculty of Medicine and Health::Sydney School of Public Healthen
usyd.citation.volume9en
usyd.citation.issue3en
usyd.citation.spage1en
usyd.citation.epage7en
workflow.metadata.onlyNoen


Show simple item record

Associated file/s

Associated collections

Show simple item record

There are no previous versions of the item available.